To assess the effects of systemic chemotherapy and biological therapy, either alone or in combination, on overall survival (OS) and progression-free survival (PFS) in patients with advanced gastric and oesophago-gastric junction (OGJ) adenocarcinoma, whose disease has progressed or relapsed on first line fluoropyrimidine and platinum-containing chemotherapy.Secondary objectives
- To assess the effect of the aforementioned intervention on tumour response, adverse effects and quality of life;
- To assess the impact of patients' geographical regions (East and South-East Asia versus regions other than East and South-East Asia) on the survival benefit of salvage systemic therapy for advanced gastric and OGJ adenocarcinoma; and
- To compare the survival benefit of salvage systemic therapy for advanced gastric and OGJ adenocarcinoma in second versus third line setting.
This is a protocol.